Agraplat

Agraplat

Manufacturer:

Ajanta Pharma Phil

Distributor:

Metro Drug
Concise Prescribing Info
Contents
Ticagrelor
Indications/Uses
Reduces the rate of CV death, MI, & stroke in patients w/ acute coronary syndrome (ACS) or history of MI. Reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
Dosage/Direction for Use
Adult Management of ACS Initially 180 mg as loading dose then 90 mg bid during the 1st yr after an ACS event. Use w/ a daily maintenance dose of aspirin 75-100 mg.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. High risk of recurrent intracranial hemorrhage (ICH) in patients w/ history of ICH. Active pathological bleeding eg, peptic ulcer or ICH.
Special Precautions
May increase risk of bleeding; stopping treatment increases risk of subsequent CV events, if possible, manage bleeding w/o discontinuing treatment. May develop new, prolonged, or worsened dyspnea. Discontinue in the case of intolerable dyspnea & consider prescribing another antiplatelet agent. Increased risk of MI, stroke, & death when discontinued. Interrupt therapy for 5 days prior to surgery w/ major risk of bleeding, then resume as soon as hemostasis is achieved. Concomitant aspirin maintenance dose. Avoid use in patients w/ severe hepatic impairment. Renal & mild to moderate hepatic impairment. Pregnancy & lactation. Childn.
Adverse Reactions
Drug Interactions
Increased exposure & risk of dyspnea, bleeding, & other adverse events w/ strong CYP3A inhibitors (eg, ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir & telithromycin). Reduced exposure & decreased efficacy w/ strong CYP3A inducers (eg, rifampin, phenytoin, carbamazepine & phenobarb). Reduced effectiveness w/ aspirin maintenance doses >100 mg. Increased serum conc of simvastatin & lovastatin; avoid simvastatin & lovastatin >40 mg. Inhibits P-gp transporter; monitor digoxin levels w/ initiation of or change in therapy.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AC24 - ticagrelor ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Presentation/Packing
Form
Agraplat FC tab 90 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in